Inactive Instrument

Highlights Sigilon Therapeutics, Inc.

Equities

SGTX

US82657L2060

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Eli Lilly Completes Purchase of Sigilon Therapeutics in Cash Deal	23-08-14	MT
Eli Lilly Completes Acquisition of Sigilon Therapeutics	23-08-14	MT
Eli Lilly and Company completed the acquisition of remaining 91.56% stake in Sigilon Therapeutics, Inc. from Flagship Ventures Fund V, L.P. and Flagship Pioneering Special Opportunities Fund II, L.P., managed by Flagship Pioneering and others.	23-08-10	CI
Sigilon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Eli Lilly to buy Sigilon Therapeutics to expand diabetes treatments	23-06-29	RE
Eli Lilly to Acquire Sigilon Therapeutics in Deal Potentially Worth More Than $300 Million; Sigilon Shares Surge	23-06-29	MT
Eli Lilly to Buy Chronic Disease-focused Sigilon Therapeutics	23-06-29	MT
Eli Lilly to Acquire Sigilon Therapeutics	23-06-29	DJ
Eli Lilly and Company entered into a definitive agreement to acquire remaining 91.55% stake in Sigilon Therapeutics, Inc. from Flagship Ventures Fund V, L.P. and Flagship Pioneering Special Opportunities Fund II, L.P., managed by Flagship Pioneering and others for $36.3 million.	23-06-28	CI
Sigilon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
SIGILON THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-03-14	AQ
Sigilon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
Sigilon Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-14	CI
Sigilon Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-14	CI
Sigilon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
SIGILON THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-08-04	AQ
Sigilon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-04	CI
Sigilon Therapeutics Gets Bid-Price Non-Compliance Notice From Nasdaq	22-06-23	MT
SIGILON THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-05-12	AQ
Sigilon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sigilon Therapeutics, Inc.

Equities

SGTX

US82657L2060

Highlights

Filters